LABELS · beacc534-14e1-4fd2-978f-5646edd537f0

Ayvakit

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2026-08-05
Captured: 2026-09-09T23:37:58.719708+00:00
Current indication reconciliation: Not reconciled

Indications and usage: exact source text

1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] .

Full extracted label fields

application numbers

NDA212608

boxed warning exact

brand names

Ayvakit

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=645c887c-8cd4-4623-8da9-ac223d71a8b9

generic names

AVAPRITINIB

beacc534-14e1-4fd2-978f-5646edd537f0

indications and usage exact

1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] .

indications and usage tables exact

is original packager

true

manufacturer names

Blueprint Medicines Corporation

matched search terms

leukemia
tumor
neoplasm
mastocytosis

package ndcs

72064-110-30
72064-120-30
72064-130-30
72064-125-30
72064-150-30

product ndcs

72064-110
72064-120
72064-130
72064-125
72064-150

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

2272112
2272118
2272120
2272122
2272124
2272126
2559723
2559725
2559727
2559729

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00600.json

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA212608

brand names

Ayvakit

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 486
end exclusive: true
exact text: 1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an ass
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 0

current approval status

not_reconciled

duplicate text group

dup-5146f009c77c471f0bba

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-0e81aaa0a849fc96687b

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 32

qualifier mentions

context exact
for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-d
kind
age
polarity
not_inferred
span
end
130
end exclusive
true
exact text
adults
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
124
context exact
l Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, in
kind
biomarker
polarity
not_inferred
span
end
195
end exclusive
true
exact text
metastatic GIST harboring a platelet-derive
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
152
context exact
ntestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18
kind
stage_or_setting
polarity
not_inferred
span
end
183
end exclusive
true
exact text
unresectable or metastatic GIST harboring a pla
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
136

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 286
end exclusive: true
exact text: 1 INDICATIONS AND USAGE AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations.
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 2 · positive indication candidate

application numbers

NDA212608

brand names

Ayvakit

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 583
end exclusive: true
exact text: tromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 87

current approval status

not_reconciled

duplicate text group

dup-709b4b1a9deb5e7314ee

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-1dc9a5de8e01b85c4e7d

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 32

qualifier mentions

context exact
2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM.
kind
age
polarity
not_inferred
span
end
371
end exclusive
true
exact text
adult patients
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
357
context exact
( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM.
kind
stage_or_setting
polarity
not_inferred
span
end
344
end exclusive
true
exact text
Advanced Systemic Mastocytosis (AdvSM) the
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
301

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 383
end exclusive: true
exact text: ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM.
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 287

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · positive indication candidate

application numbers

NDA212608

brand names

Ayvakit

classification reasons

inherited_predicate_from_same_label_section_requires_review
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 756
end exclusive: true
exact text: elet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatme
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 184

current approval status

not_reconciled

duplicate text group

dup-cfa06c146391a42bfefd

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-7c1ab2494e0079d4c84b

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

end: 63
end exclusive: true
exact text: is a kinase inhibitor indicated
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 32

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 556
end exclusive: true
exact text: AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 384

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 4 · limitation of use

application numbers

NDA212608

brand names

Ayvakit

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 986
end exclusive: true
exact text: adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 357

current approval status

not_reconciled

duplicate text group

dup-d5a874bf57db7e478744

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-16e300756701d3b6e2a1

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

Source null

qualifier mentions

context exact
1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM.
kind
age
polarity
not_inferred
span
end
776
end exclusive
true
exact text
adult patients
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
762

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 786
end exclusive: true
exact text: ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM.
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 557

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 5 · limitation of use

application numbers

NDA212608

brand names

Ayvakit

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1135
end exclusive: true
exact text: VAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 587

current approval status

not_reconciled

duplicate text group

dup-756e370364c84248a5a4

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-63bdafde5593c861d09f

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 935
end exclusive: true
exact text: ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 )
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 787

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · positive indication candidate

application numbers

NDA212608

brand names

Ayvakit

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1484
end exclusive: true
exact text: is (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic masto
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 736

current approval status

not_reconciled

duplicate text group

dup-e1c75701d5d4de953168

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-19c9b5e97f7797a9cd9a

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

end: 1060
end exclusive: true
exact text: is indicated
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1048

qualifier mentions

context exact
al Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-d
kind
age
polarity
not_inferred
span
end
1088
end exclusive
true
exact text
adults
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1082
context exact
1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults wit
kind
biomarker
polarity
not_inferred
span
end
1032
end exclusive
true
exact text
Metastatic Gastrointestinal Stromal Tumor (
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
989
context exact
indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, in
kind
biomarker
polarity
not_inferred
span
end
1153
end exclusive
true
exact text
metastatic GIST harboring a platelet-derive
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1110
context exact
1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment o
kind
stage_or_setting
polarity
not_inferred
span
end
1020
end exclusive
true
exact text
Unresectable or Metastatic Gastrointestinal Str
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
973
context exact
ST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18
kind
stage_or_setting
polarity
not_inferred
span
end
1141
end exclusive
true
exact text
unresectable or metastatic GIST harboring a pla
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1094

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1284
end exclusive: true
exact text: 1.1 PDGFRA Exon 18 Mutation-Positive Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST) AYVAKIT ® is indicated for the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] .
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 936

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 7 · positive indication candidate

application numbers

NDA212608

brand names

Ayvakit

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1629
end exclusive: true
exact text: lts with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAK
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1085

current approval status

not_reconciled

duplicate text group

dup-701000626ffec9673696

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-a668ba96c5557ce9199c

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

end: 1348
end exclusive: true
exact text: is indicated
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1336

qualifier mentions

context exact
tocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM).
kind
age
polarity
not_inferred
span
end
1384
end exclusive
true
exact text
adult patients
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1370
context exact
1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with ad
kind
stage_or_setting
polarity
not_inferred
span
end
1332
end exclusive
true
exact text
Advanced Systemic Mastocytosis (AdvSM) AYVA
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1289
context exact
VAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM).
kind
stage_or_setting
polarity
not_inferred
span
end
1428
end exclusive
true
exact text
advanced systemic mastocytosis (AdvSM)
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1390

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1429
end exclusive: true
exact text: 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM).
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1285

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · unclassified context

application numbers

NDA212608

brand names

Ayvakit

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 1802
end exclusive: true
exact text: 42V mutations [see Dosage and Administration (2.2) ] . 1.2 Advanced Systemic Mastocytosis (AdvSM) AYVAKIT is indicated for the treatment of adult patients with advanced systemic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic M
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1230

current approval status

not_reconciled

duplicate text group

dup-cfa06c146391a42bfefd

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-6c2c39df70991e9d6834

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1602
end exclusive: true
exact text: AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1430

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 9 · limitation of use

application numbers

NDA212608

brand names

Ayvakit

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1978
end exclusive: true
exact text: emic mastocytosis (AdvSM). AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM). Limitations of Use : AYVAKIT is not recommended for the tr
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1403

current approval status

not_reconciled

duplicate text group

dup-2cdf5b594e544af5625e

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-2fd520db7fa508b37925

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1778
end exclusive: true
exact text: Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] .
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1603

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 10 · positive indication candidate

application numbers

NDA212608

brand names

Ayvakit

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 2093
end exclusive: true
exact text: st cell leukemia (MCL). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] .
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1579

current approval status

not_reconciled

duplicate text group

dup-215d7589c9815c1de7b9

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-a827169bb5e7f2ad5194

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

end: 1840
end exclusive: true
exact text: is indicated
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1828

qualifier mentions

context exact
astocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).
kind
age
polarity
not_inferred
span
end
1876
end exclusive
true
exact text
adult patients
label id
beacc534-14e1-4fd2-978f-5646edd537f0
offset unit
unicode_code_points
source array index
0
source field
indications_and_usage_exact
source text sha256
7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start
1862

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 1919
end exclusive: true
exact text: 1.3 Indolent Systemic Mastocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1779

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 11 · limitation of use

application numbers

NDA212608

brand names

Ayvakit

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 2093
end exclusive: true
exact text: than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] . 1.3 Indolent Systemic Mastocytosis (ISM) AYVAKIT is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM). Limitations of Use : AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] .
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1720

current approval status

not_reconciled

duplicate text group

dup-73ea2ba6515bd5959470

extraction review status

automated_candidate_pending_source_review

generic names

AVAPRITINIB

ind-span-1eaab85d72d6834197f3

label id

beacc534-14e1-4fd2-978f-5646edd537f0

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

a9df7a5786dc51557d38f2a0881b5b5e9ae02ae396a6798e39ac96f586bcc5e6

source defined aliases

source span

end: 2093
end exclusive: true
exact text: Limitations of Use : AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L [see Warnings and Precautions (5.1) ] .
label id: beacc534-14e1-4fd2-978f-5646edd537f0
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 7867c82801d4446497faf936d9d27cc491b504aab98a246c8abaeaa040337b58
start: 1920

source url

https://api.fda.gov/drug/label.json?search=id%3A%22beacc534-14e1-4fd2-978f-5646edd537f0%22

spl effective date

2026-08-05

spl set id

645c887c-8cd4-4623-8da9-ac223d71a8b9

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice